A treatment strategy for Graves' orbitopathy

Nature Clinical Practice Endocrinology and Metabolism

Volumn 3, Issue 5, 2007, Pages 430-436

  Marcocci, Claudio ^a   Pinchera, Aldo ^a   Marinò, Michele ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Glucocorticoids; Graves' disease; Graves' orbitopathy; Ophthalmopathy; Thyroid disease

Indexed keywords

GLUCOCORTICOID; LEVOTHYROXINE; METHYLPREDNISOLONE; PREDNISONE; THIAMAZOLE;

ADULT; ARTICLE; BLOOD ANALYSIS; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIPLOPIA; DISEASE SEVERITY; DRUG WITHDRAWAL; ENDOCRINE OPHTHALMOPATHY; EXOPHTHALMOS; EYE MOVEMENT; EYELID; FEMALE; GRAVES DISEASE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; IRRADIATION; LABORATORY TEST; NODULAR GOITER; OCCULT BLOOD; OPHTHALMOLOGY; OPTIC NERVE DISEASE; PRIORITY JOURNAL; THYROID CRISIS; THYROID FUNCTION TEST; THYROIDECTOMY; VISUAL ACUITY;

ANTITHYROID AGENTS; FEMALE; GLUCOCORTICOIDS; GRAVES OPHTHALMOPATHY; HUMANS; METHIMAZOLE; MIDDLE AGED; ORBITAL DISEASES; RADIOTHERAPY; THYROXINE;

EID: 34247550145     PISSN: 17458366     EISSN: 17458374     Source Type: Journal    
DOI: 10.1038/ncpendmet0500     Document Type: Article

References (15)

1. Pinchera A et al. (1992) Classification of eye changes of Graves' disease. Thyroid 2: 235-236
2. Marcocci C et al. (2001) Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab 86: 3562-3567
3. Vitti P et al. (2003) Europe is iodine deficient [letter]. Lancet 361: 1226
4. Eckstein AK et al. (2006) Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 91: 3464-3470
5. Bartalena L et al. (2004) Relationship between management of hyperthyroidism and course of the ophthalmopathy. J Endocrinol Invest 27: 288-294
6. Bartalena L et al. (2000) Management of Graves' ophthalmopathy: reality and perspectives. Endocr Rev 21: 168-199
7. Marinò M et al. (2004) Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves' ophthalmopathy. Thyroid 5: 403-406
8. Dourakis SP et al. (2002) Acute severe steatohepatitis related to prednisone therapy. Am J Gastroenterol 97: 1074-1075
9. Marinò M et al. (2005) Autoimmune hepatitis during intravenous glucocorticoid pulse therapy for Graves' ophthalmopathy treated successfully with glucocorticoids themselves. J Endocrinol Invest 28: 280-284
10. Wakelkamp IMM et al. (2005) Surgical or medical decompression as a first-line treatment of optic neuropathy in Graves' ophthalmopathy? A randomized controlled trial. Clin Endocrinol (Oxf) 63: 323-328
11. Wiersinga WM et al. (2006) Clinical assessment of patients with Graves' orbitopathy: the European Group on Graves' Orbitopathy recommendations to generalists, specialists and clinical researchers. Eur J Endocrinol 155: 387-389
12. European Group on Graves' orbitopathy [www.eugogo.org] (Accessed 9 March 2007)
13. Kahaly GJ et al. (2005) Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy. J Clin Endocrinol Metab 90: 5234-5240
14. Marcocci C et al. (2004) Novel aspects of immunosuppressive and radiotherapy management of Graves' ophthalmopathy. J Endocrinol Invest 27: 272-280
15. Marcocci C et al. (2003) Long-term safety of orbital radiotherapy for Graves' ophthalmopathy. J Clin Endocrinol Metab 88: 3561-3566